Objective. To evaluate what types of DNA damages are detected in rheumatoid arthritis (RA). Methods. The DNA adducts such as 8-oxo-hydroxy-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG), 1,N6-etheno-2′-deoxyadenosine (εdA), and heptanone-etheno-2′-deoxycytidine (HεdC) in genomic DNAs, derived from whole blood cells from 46 RA patients and 31 healthy controls, were analyzed by high-performance liquid chromatography tandem mass spectrometry, and their levels in RA patients and controls were compared. In addition, correlation between DNA adducts and clinical parameters of RA was analyzed. Results. Compared with controls, the levels of HεdC in RA were significantly higher ( ) and age dependent (r = 0.43, P < 0.01), while there was no significant difference in 8-oxo-dG and εdA accumulation between RA patients and controls. HεdC levels correlated well with the number of swollen joints (r = 0.57, P < 0.0001) and weakly with the number of tender joints (r = 0.26, P = 0.08) of RA patients, while they did not show a significant association with serological markers such as C-reactive protein and matrix metalloproteinase 3. Conclusion. These findings indicate that HεdC may have some influence on the development of RA and/or its complications. 1. Introduction Rheumatoid arthritis (RA) is a systemic, chronic inflammatory disease of the joints and surrounding tissues, accompanied by intense pain, irreversible joint destruction, and systemic complications [1]. Its etiology has not been fully clarified yet, but oxidative stress is one of the pathological factors, which contribute to its development [2–5]. Shao et al. recently reported detecting the presence of DNA damage and deficiency of the DNA repair enzyme, ataxia telangiectasia mutated (ATM), in RA T cells [6]. Moreover, a DNA oxidation product, 8-oxo-hydroxy-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG), has been shown to be highly expressed in RA patients [2]. DNA damage induced by exposure to ionizing radiation, ultraviolet light, and exogenous or endogenous chemical mutagens causes DNA strand breakages, which are thought to be mutagenic, carcinogenic, and aging factors [2]. Additionally as new DNA damage, lipid peroxidation-derived DNA adducts have been recently reported in human [7], and lipid peroxidation has been also considered as a factor of the pathogenesis or the local inflammatory response of RA [4, 8–10]. Representative DNA adducts are 8-oxo-dG, 1,N6-etheno-2′-deoxyadenosine (εdA), and heptanone-etheno-2′-deoxycytidine (HεdC); the latter two of which are direct reactive oxygen species- (ROS-) derived and lipid
References
[1]
I. B. McInnes and G. Schett, “The pathogenesis of rheumatoid arthritis,” The New England Journal of Medicine, vol. 365, no. 23, pp. 2205–2219, 2011.
[2]
S. Bashir, G. Harris, M. A. Denman, D. R. Blake, and P. G. Winyard, “Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases,” Annals of the Rheumatic Diseases, vol. 52, no. 9, pp. 659–666, 1993.
[3]
Y. Ozkan, S. Yardym-Akaydyn, A. Sepici, E. Keskin, V. Sepici, and B. Simsek, “Oxidative status in rheumatoid arthritis,” Clinical Rheumatology, vol. 26, no. 1, pp. 64–68, 2007.
[4]
C. A. Hitchon and H. S. El-Gabalawy, “Oxidation in rheumatoid arthritis,” Arthritis Research and Therapy, vol. 6, no. 6, pp. 265–278, 2004.
[5]
O. Altindag, M. Karakoc, A. Kocyigit, H. Celik, and N. Soran, “Increased DNA damage and oxidative stress in patients with rheumatoid arthritis,” Clinical Biochemistry, vol. 40, no. 3-4, pp. 167–171, 2007.
[6]
L. Shao, H. Fujii, I. Colmegna, H. Oishi, J. J. Goronzy, and C. M. Weyand, “Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis,” Journal of Experimental Medicine, vol. 206, no. 6, pp. 1435–1449, 2009.
[7]
P.-H. Chou, S. Kageyama, S. Matsuda et al., “Detection of lipid peroxidation-induced DNA adducts caused by 4-oxo-2(E)-nonenal and 4-oxo-2(E)-hexenal in human autopsy tissues,” Chemical Research in Toxicology, vol. 23, no. 9, pp. 1442–1448, 2010.
[8]
B. Liagre, P. Vergne, M. Rigaud, and J.-L. Beneytout, “Arachidonate 15-lipoxygenase of reticulocyte-type in human rheumatoid arthritis type B synoviocytes and modulation of its activity by proinflammatory cytokines,” The Journal of Rheumatology, vol. 26, no. 5, pp. 1044–1051, 1999.
[9]
E. Ferrante, N. Vazzana, F. Santilli et al., “Determinants of thromboxane biosynthesis in rheumatoid arthritis: role of RAGE and oxidant stress,” Free Radical Biology and Medicine, vol. 49, no. 5, pp. 857–864, 2010.
[10]
G. Baskol, H. Demir, M. Baskol et al., “Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis,” Cell Biochemistry and Function, vol. 24, no. 4, pp. 307–311, 2006.
[11]
F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 315–324, 1988.
[12]
R. A. Kanaly, S. Matsui, T. Hanaoka, and T. Matsuda, “Application of the adductome approach to assess intertissue DNA damage variations in human lung and esophagus,” Mutation Research, vol. 625, no. 1-2, pp. 83–93, 2007.
[13]
M. Pollack, T. Oe, S. H. Lee, M. V. S. Elipe, B. H. Arison, and I. A. Blair, “Characterization of 2′-deoxycytidine adducts derived from 4-oxo-2-nonenal, a novel lipid peroxidation product,” Chemical Research in Toxicology, vol. 16, no. 7, pp. 893–900, 2003.
[14]
I. A. Blair, “DNA adducts with lipid peroxidation products,” The Journal of Biological Chemistry, vol. 283, no. 23, pp. 15545–15549, 2008.
[15]
A. Seven, S. Güzel, M. Aslan, and V. Hamuryudan, “Lipid, protein, DNA oxidation and antioxidant status in rheumatoid arthritis,” Clinical Biochemistry, vol. 41, no. 7-8, pp. 538–543, 2008.
[16]
P. I. Mapp, M. C. Grootveld, and D. R. Blake, “Hypoxia, oxidative stress and rheumatoid arthritis,” British Medical Bulletin, vol. 51, no. 2, pp. 419–436, 1995.
[17]
S. Kundu, P. Ghosh, S. Datta, A. Ghosh, S. Chattopadhyay, and M. Chatterjee, “Oxidative stress as a potential biomarker for determining disease activity in patients with rheumatoid arthritis,” Free Radical Research, vol. 46, no. 12, pp. 1482–1489, 2012.
[18]
Y. Kageyama, M. Takahashi, T. Nagafusa, E. Torikai, and A. Nagano, “Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis,” Rheumatology International, vol. 28, no. 3, pp. 245–251, 2008.
[19]
L. L. Bhusate, K. E. Herbert, D. L. Scott, and D. Perrett, “Increased DNA strand breaks in mononuclear cells from patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 51, no. 1, pp. 8–12, 1992.
[20]
M. V. Williams, S. H. Lee, M. Pollack, and I. A. Blair, “Endogenous lipid hydroperoxide-mediated DNA-adduct formation in min mice,” The Journal of Biological Chemistry, vol. 281, no. 15, pp. 10127–10133, 2006.
[21]
L. Dai, D. J. Lamb, D. S. Leake et al., “Evidence for oxidised low density lipoprotein in synovial fluid from rheumatoid arthritis patients,” Free Radical Research, vol. 32, no. 6, pp. 479–486, 2000.
[22]
J. D. West, C. Ji, S. T. Duncan et al., “Induction of apoptosis in colorectal carcinoma cells treated with 4-hydroxy-2-nonenal and structurally related aldehydic products of lipid peroxidation,” Chemical Research in Toxicology, vol. 17, no. 4, pp. 453–462, 2004.
[23]
I.-Y. Yang, K. Hashimoto, N. de Wind, I. A. Blair, and M. Moriya, “Two distinct translesion synthesis pathways across a lipid peroxidation-derived DNA adduct in mammalian cells,” The Journal of Biological Chemistry, vol. 284, no. 1, pp. 191–198, 2009.
[24]
M. J. Picklo, A. Azenkeng, and M. R. Hoffmann, “Trans-4-oxo-2-nonenal potently alters mitochondrial function,” Free Radical Biology and Medicine, vol. 50, no. 2, pp. 400–407, 2011.
[25]
J. A. Doorn, S. K. Srivastava, and D. R. Petersen, “Aldose reductase catalyzes reduction of the lipid peroxidation product 4-oxonon-2-enal,” Chemical Research in Toxicology, vol. 16, no. 11, pp. 1418–1423, 2003.
[26]
M. Pollack, I.-Y. Yang, H. Y. Kim, I. A. Blair, and M. Moriya, “Translesion DNA synthesis across the heptanone-etheno-2′- deoxycytidine adduct in cells,” Chemical Research in Toxicology, vol. 19, no. 8, pp. 1074–1079, 2006.
[27]
Y. Kageyama, M. Takahashi, T. Nagafusa, E. Torikai, and A. Nagano, “Methotrexate reduces the levels of pentosidine and 8-hydroxy-deoxy guanosine in patients with rheumatoid arthritis,” Modern Rheumatology, vol. 17, no. 5, pp. 398–402, 2007.
[28]
G. Gridley, J. K. McLaughlin, A. Ekbom et al., “Incidence of cancer among patients with rheumatoid arthritis,” Journal of the National Cancer Institute, vol. 85, no. 4, pp. 307–311, 1993.
[29]
L. Mellemkj？r, M. S. Linet, G. Gridley, M. Frisch, H. M？ller, and J. H. Olsen, “Rheumatoid arthritis and cancer risk,” European Journal of Cancer A, vol. 32, no. 10, pp. 1753–1757, 1996.
